TNBCs constitute 10–24% of all breast cancers, are most aggressive, and possess higher metastatic potential when compared to other types of breast cancer which are positive for either one or a combination of the ER, PR, or HER2 receptors [8,9,346,347]. The gene discussed is ESR1; the disease is breast carcinoma.